Stereotactic Body Radiotherapy (SBRT) is now a standard of care for the treatment for clinically localized prostate cancer (low through very high risk) by NCCN guidelines with emerging data for regional and oligometastatic disease sufficiently justifying its use for these indications also. Additionally, data suggest that SBRT in the post-prostatectomy setting can be delivered safely. Due to the biological properties, prostate cancer behaves more like late reacting tissue with a low ratio. Hence, increasing fraction size may increase the therapeutic ratio with increasing fraction size.
Thousands of patients have now been treated in prospective trials with SBRT for prostate cancer with excellent long-term efficacy and toxicity, although the acute toxicity might be increased as compared to conventional fractionation. New radiation techniques, fractionation schemes, and devices (such as hydrogels) have been implemented which have resulted in reductions in acute and late toxicity.
The goal of this Research Topic is to provide a single source for clinicians in academics and in private practice.
This Research Topic welcomes manuscripts which cover all aspects of SBRT for the prostate. This involves:
-Clinical Trials
-Retrospective and prospective studies
-Reviews of the literature upon invitation
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Stereotactic Body Radiotherapy (SBRT) is now a standard of care for the treatment for clinically localized prostate cancer (low through very high risk) by NCCN guidelines with emerging data for regional and oligometastatic disease sufficiently justifying its use for these indications also. Additionally, data suggest that SBRT in the post-prostatectomy setting can be delivered safely. Due to the biological properties, prostate cancer behaves more like late reacting tissue with a low ratio. Hence, increasing fraction size may increase the therapeutic ratio with increasing fraction size.
Thousands of patients have now been treated in prospective trials with SBRT for prostate cancer with excellent long-term efficacy and toxicity, although the acute toxicity might be increased as compared to conventional fractionation. New radiation techniques, fractionation schemes, and devices (such as hydrogels) have been implemented which have resulted in reductions in acute and late toxicity.
The goal of this Research Topic is to provide a single source for clinicians in academics and in private practice.
This Research Topic welcomes manuscripts which cover all aspects of SBRT for the prostate. This involves:
-Clinical Trials
-Retrospective and prospective studies
-Reviews of the literature upon invitation
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
